The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has made public a new report including recommendations on silent epidemic, called Hepatitis. The report, titled “Towards a Sustainable, Intersectoral Approach to Viral Hepatitis, aims to encourage a comprehensive approach to fighting Hepatitis. It is meant to inform the upcoming discussion at the 67thWorld Health Assembly.
Hepatitis B and C (HBV, HCV) are devastating viral diseases which are more common than HIV/AIDS. The virus progresses very slowly over the years. As a result many patients are unaware that they are infected until serious complications emerge. 15 to 30 percent of people with chronic HCV infection will develop cirrhosis; HCV is the major cause of liver cancer. Viral hepatitis is responsible for 1.6 million deaths each year causing individual suffering and putting a huge cost to society in terms of lost productivity and cost of healthcare services.
“We have devoted substantial efforts to developing prevention and treatment options and are making all necessary efforts to bring up solutions that further increase cure rates and reduce treatment duration and toxicity, saysEduardo Pisani, IFPMA Director General.
“However, treatment is only part of the picture. Experience our industry gained through health partnerships in low- and middle-income countries makes it clear that to address hepatitis we need a comprehensive approach that combines research, prevention, screening and care. We need to act together to stop this silent epidemic,” Pisani adds.
While 95 percent of HBV patients could be treated and 90 percent of HCV patients potentially cured, at most 20 percent and 2 to 3 percent of them respectively receive adequate treatment. IFPMA’s Report contributes to the global health discussion on the best way of fighting the epidemic. It recommends a comprehensive approach to:
- Raise awareness and improve the understanding of viral hepatitis and prevention methods, both among health professionals and individuals (including also prevention of nosocomial transmission and special focus on vulnerable high-risk groups).
- Continue implementing vaccination programmes against HBV.
- Collect reliable data on the epidemiology and burden of viral hepatitis.
- Improve funding and availability of screening to help patients seek early diagnosis and improved funding for treatment programmes.
- Develop comprehensive care networks with embedded standards of care.
- Leverage existing HIV infrastructure to improve detection and treatment rates for co-infected people.
SOURCE: International Federation of Pharmaceutical Manufacturers & Associations